Biological Basis of Combined Radio- and Chemotherapy

  • Claus Belka
  • Carsten Nieder
  • Michael Molls
Part of the Medical Radiology book series (MEDRAD)


Clin Oncol Radiat Oncol Biol Phys Spatial Interaction Biliary Tract Cancer Hypoxic Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bartelink H, Roelofsen F, Eschwege F et al (1997) Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 15:2040–2049PubMedGoogle Scholar
  2. Baumann M, Liertz C, Baisch H et al (1994) Impact of overall treatment time of fractionated irradiation on local control of human FaDu squamous cell carcinoma in nude mice. Radiother Oncol 32:137–143PubMedCrossRefGoogle Scholar
  3. Beck-Bornholdt HP, Dubben HH, Liertz-Petersen C, Willers H (1997) Hyperfractionation: Where do we stand? Radiother Oncol 43:1–21PubMedCrossRefGoogle Scholar
  4. Begg AC (1990) Cisplatin and radiation: interaction probabilities and therapeutic possibilities. Int J Radiat Oncol Biol Phys 19:1183–1189PubMedGoogle Scholar
  5. Belka C (2005) The fate of irradiated tumor cells. Oncogene, epubGoogle Scholar
  6. Berrios M, Osheroff N, Fisher PA (1985) In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophila nuclear matrix fraction. Proc Natl Acad Sci USA 82:4142–4146PubMedCrossRefGoogle Scholar
  7. Bolla M, Collette L, Blank L et al (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360:103–106PubMedCrossRefGoogle Scholar
  8. Brizel DM, Albers ME, Fisher SR et al (1998) Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338:1798–1804PubMedCrossRefGoogle Scholar
  9. Buda A, Fossati R, Colombo N et al (2005) Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 Italian Collaborative Study. J Clin Oncol 23:4137–4145PubMedCrossRefGoogle Scholar
  10. Budach V, Stuschke M, Budach W et al (2005) Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 23:1125–1135PubMedCrossRefGoogle Scholar
  11. Budach W, Gioioso D, Taghian A et al (1997) Repopulation capacity during fractionated irradiation of squamous cell carcinomas and glioblastomas in vitro. Int J Radiat Oncol Biol Phys 39: 743–750PubMedCrossRefGoogle Scholar
  12. Budach W, Paulsen F, Welz S et al (2002) Mitomycin C in combination with radiotherapy as a potent inhibitor of tumour cell repopulation in a human squamous cell carcinoma. Br J Cancer 86:470–476PubMedCrossRefGoogle Scholar
  13. Chang HJ, Jung KH, Kim DY et al (2005) Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma. Hum Pathol 36:364–371PubMedCrossRefGoogle Scholar
  14. Dische S, Saunders M, Barrett A et al (1997) A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 44:123–136PubMedCrossRefGoogle Scholar
  15. Durand RE, LePard NE (1994) Modulation of tumor hypoxia by conventional chemotherapeutic agents. Int J Radiat Oncol Biol Phys 29:481–486PubMedGoogle Scholar
  16. Durand RE, LePard NE (2000) Effects of mitomycin C on the oxygenation and radiosensitivity of murine and human tumours in mice. Radiother Oncol 56:245–252PubMedCrossRefGoogle Scholar
  17. Earnshaw WC, Heck MM (1985) Localization of topoisomerase II in mitotic chromosomes. J Cell Biol 100:1716–1725PubMedCrossRefGoogle Scholar
  18. Efferth T, Volm M (2005) Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther 107:155–176PubMedCrossRefGoogle Scholar
  19. Eliaz RE, Nir S, Marty C, Szoka FC Jr (2004) Determination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes. Cancer Res 64:711–718PubMedCrossRefGoogle Scholar
  20. Epstein RJ (1990) Drug-induced DNA damage and tumor chemosensitivity. J Clin Oncol 8:2062–2084PubMedGoogle Scholar
  21. Evans TR, Yellowlees A, Foster E et al (2005) Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol 23:2988–2995PubMedCrossRefGoogle Scholar
  22. Farquhar C, Marjoribanks J, Basser R et al (2005) High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. Cochrane Database Syst Rev:CD003142Google Scholar
  23. Forastiere AA, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091–2098PubMedCrossRefGoogle Scholar
  24. Geard CR, Jones JM (1994) Radiation and taxol effects on synchronized human cervical carcinoma cells. Int J Radiat Oncol Biol Phys 29:565–569PubMedGoogle Scholar
  25. Gerard J, Romestaing P, Bonnetain F et al (2005) Preoperative chemoradiotherapy (CT-RT) improves local control in T3-4 rectal cancers: results of the FFCD 9203 randomized trial (Abstract). Int J Radiat Oncol Biol Phys 63(Suppl 1): S2–S3CrossRefGoogle Scholar
  26. Giocanti N, Hennequin C, Balosso J et al (1993) DNA repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide. Cancer Res 53:2105–2111PubMedGoogle Scholar
  27. Grau C, Overgaard J (1988) Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother Oncol 13:301–309PubMedCrossRefGoogle Scholar
  28. Green JA, Kirwan JM, Tierney JF et al (2001) Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 358:781–786PubMedCrossRefGoogle Scholar
  29. Guner D, Belka C, Daniel PT (2003) Disruption of cell death signaling in cancer: impact on disease prognosis and response to therapy. Curr Med Chem Anti-Canc Agents 3:319–326CrossRefGoogle Scholar
  30. Hartley A, Ho KF, McConkey C, Geh JI (2005) Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: analysis of phase II/III trials. Br J Radiol 78:934–938PubMedCrossRefGoogle Scholar
  31. Hennequin C, Giocanti N, Favaudon V (1996) Interaction of ionizing radiation with paclitaxel (taxol) and docetaxel (taxotere) in HeLa and SQ20B cells. Cancer Res 56:1842–1850PubMedGoogle Scholar
  32. Henness S, Davey MW, Harvie RM, Davey RA (2002) Fractionated irradiation of H69 small-cell lung cancer cells causes stable radiation and drug resistance with increased MRP1, MRP2, and topoisomerase II alpha expression. Int J Radiat Oncol Biol Phys 54:895–902PubMedCrossRefGoogle Scholar
  33. Hill BT, Moran E, Etievant C et al (2000) Low-dose twice-daily fractionated X-irradiation of ovarian tumor cells in vitro generates drug-resistant cells overexpressing two multidrug resistance-associated proteins, P-glycoprotein and MRP1. Anticancer Drugs 11:193–200PubMedCrossRefGoogle Scholar
  34. Horiot JC, Lopez-Torrecilla J, Begg AC et al (1997) Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 44:111–121PubMedCrossRefGoogle Scholar
  35. Kallman RF, Bedarida G, Rapacchietta D (1992) Experimental studies on schedule dependence in the treatment of cancer with combinations of chemotherapy and radiotherapy. Front Radiat Ther Oncol 26:31–44PubMedGoogle Scholar
  36. Kim JH, Kim SH, Kolozsvary A, Khil MS (1992) Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. Int J Radiat Oncol Biol Phys 22:515–518PubMedGoogle Scholar
  37. Kim JJ, Tannock IF (2005) Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 5:516–525PubMedCrossRefGoogle Scholar
  38. Lawrence TS, Davis MA, Maybaum J (1994) Dependence of 5-fluorouracil-mediated radiosensitization on DNA-directed effects. Int J Radiat Oncol Biol Phys 29:519–523PubMedGoogle Scholar
  39. Lawrence TS, Davis MA, Tang HY, Maybaum J (1996a) Fluorodeoxyuridinemediated cytotoxicity and radiosensitization require S phase progression. Int J Radiat Biol 70:273–280PubMedCrossRefGoogle Scholar
  40. Lawrence TS, Davis MA, Loney TL (1996b) Fluoropyrimidinemediated radiosensitization depends on cyclin E-dependent kinase activation. Cancer Res 56:3203–3206PubMedGoogle Scholar
  41. Lawrence TS, Chang EY, Hahn TM (1996c) Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys 34:867–872PubMedCrossRefGoogle Scholar
  42. Lawrence TS, Chang EY, Hahn TM, Shewach DS (1997) Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine). Clin Cancer Res 3:777–782PubMedGoogle Scholar
  43. McGinn CJ, Miller EM, Lindstrom MJ et al (1994) The role of cell cycle redistribution in radiosensitization: implications regarding the mechanism of fluorodeoxyuridine radiosensitization. Int J Radiat Oncol Biol Phys 30:851–859PubMedGoogle Scholar
  44. McGinn CJ, Shewach DS, Lawrence TS (1996) Radiosensitizing nucleosides. J Natl Cancer Inst 88:1193–1203PubMedGoogle Scholar
  45. Milas L, Hunter NR, Mason KA et al (1994) Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res 54:3506–3510PubMedGoogle Scholar
  46. Milas L, Hunter NR, Mason KA et al (1995) Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res 55:3564–3568PubMedGoogle Scholar
  47. Miller EM, Kinsella TJ (1992) Radiosensitization by fluorodeoxyuridine: effects of thymidylate synthase inhibition and cell synchronization. Cancer Res 52:1687–1694PubMedGoogle Scholar
  48. Miller SJ, Lavker RM, Sun TT (2005) Interpreting epithelial cancer biology in the context of stem cells: tumor properties and therapeutic implications. Biochem Biophys Acta 1756:25–52PubMedGoogle Scholar
  49. Minckwitz G von, Blohmer JU, Raab G et al (2005) In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 16:56–63CrossRefGoogle Scholar
  50. Minsky BD, Pajak TF, Ginsberg RJ et al (2002) INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20:1167–1174PubMedCrossRefGoogle Scholar
  51. Modarress M, Maghami FQ, Golnavaz M et al (2005) Comparative study of chemoradiation and neoadjuvant chemotherapy effects before radical hysterectomy in stage IB-IIB bulky cervical cancer and with tumor diameter greater than 4 cm. Int J Gynecol Cancer 15:483–488PubMedCrossRefGoogle Scholar
  52. Molls M, Vaupel P (1998) Blood perfusion and microenvironment of human tumors. Springer, Berlin Heidelberg New YorkGoogle Scholar
  53. Moon Y, Todoroki T, Ohno T et al (2000) Enhanced radiation killing by 5-fluorouracil of biliary tract cancer cell lines. Int J Oncol 16:987–994PubMedGoogle Scholar
  54. Naida JD, Davis MA, Lawrence TS (1998) The effect of activation of wild-type p53 function on fluoropyrimidinemediated radiosensitization. Int J Radiat Oncol Biol Phys 41:675–680PubMedCrossRefGoogle Scholar
  55. Nehls O, Okech T, Hsieh CJ et al (2005) Low BAX protein expression correlates with disease recurrence in preoperatively irradiated rectal carcinoma. Int J Radiat Oncol Biol Phys 61:85–91PubMedCrossRefGoogle Scholar
  56. Nelson WG, Liu LF, Coffey DS (1986) Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells. Nature 322:187–189PubMedCrossRefGoogle Scholar
  57. Nieder C, Milas L, Ang KK (2003) Modification of radiation response: cytokines, growth factors, and other biological targets. Springer, Berlin Heidelberg New YorkGoogle Scholar
  58. Nielsen D, Maare C, Eriksen J et al (2001) Expression of P-glycoprotein and multidrug resistance associated protein in Ehrlich ascites tumor cells after fractionated irradiation. Int J Radiat Oncol Biol Phys 51:1050–1057PubMedCrossRefGoogle Scholar
  59. Nordsmark M, Bentzen SM, Rudat V et al (2005) Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiotherapy. An international multicenter study. Radiother Oncol 77:18–24PubMedCrossRefGoogle Scholar
  60. Pietras K, Hanahan D (2005) A multitargeted, metronomic, and maximum-tolerated dose “chemo-switch” regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23:939–952PubMedCrossRefGoogle Scholar
  61. Pinedo HM, Peters GF (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6:1653–1664PubMedGoogle Scholar
  62. Pollack A, Salem N, Ashoori F et al (2001) Lack of prostate cancer radiosensitization by androgen deprivation. Int J Radiat Oncol Biol Phys 51:1002–1007PubMedCrossRefGoogle Scholar
  63. Rau B, Sturm I, Lage H et al (2003) Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol 21:3391–3401PubMedCrossRefGoogle Scholar
  64. Reitsamer R, Peintinger F, Prokop E, Hitzl W (2005) Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer. Anticancer Drugs 16:867–870PubMedCrossRefGoogle Scholar
  65. Roach M III, DeSilvio M, Lawton C et al (2003) Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21:1904–1911PubMedCrossRefGoogle Scholar
  66. Robert J, Morvan VL, Smith D et al (2005) Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol 54:171–196PubMedGoogle Scholar
  67. Robertson JM, Shewach DS, Lawrence TS (1996) Preclinical studies of chemotherapy and radiation therapy for pancreatic carcinoma. Cancer 78:674–679PubMedGoogle Scholar
  68. Rockwell S (1982) Cytotoxicities of mitomycin C and X rays to aerobic and hypoxic cells in vitro. Int J Radiat Oncol Biol Phys 8:1035–1039PubMedGoogle Scholar
  69. Rosier JF, Beauduin M, Bruniaux M et al (1999) The effect of 2′-2′ difluorodeoxycytidine (dFdC, gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity. Int J Radiat Biol 75:245–251PubMedCrossRefGoogle Scholar
  70. Ryu JS, Um JH, Kang CD et al (2004) Fractionated irradiation leads to restoration of drug sensitivity in MDR cells that correlates with down-regulation of P-gp and DNA-dependent protein kinase activity. Radiat Res 162:527–535PubMedCrossRefGoogle Scholar
  71. Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740PubMedCrossRefGoogle Scholar
  72. Schaake-Koning C, van den Bogaert W, Dalesio O et al (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524–530PubMedCrossRefGoogle Scholar
  73. Seifert P, Baker LH, Reed ML (1975) Comparison of continuously infused 5-FU with bolus injection in treatment of patients with colorectal carcinoma. Cancer 36:123–128PubMedCrossRefGoogle Scholar
  74. Shaked Y, Emmenegger U, Francia G et al (2005) Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res 65:7045–7051PubMedCrossRefGoogle Scholar
  75. Shewach DS, Hahn TM, Chang E et al (1994) Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 54:3218–3223PubMedGoogle Scholar
  76. Shimizu D, Ishikawa T, Ichikawa Y et al (2004) Current progress in the prediction of chemosensitivity for breast cancer. Breast Cancer 11:42–48PubMedCrossRefGoogle Scholar
  77. Shimoyama M (1975) The cytocidal action of alkylating agents and anticancer antibodies against in-vitro cultured yoshida ascitis sarcoma cells. J Jpn Soc Cancer Ther 10:63–72Google Scholar
  78. Simoens C, Korst AE, De Pooter CM et al (2003) In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects. Br J Cancer 89:2305–2311PubMedCrossRefGoogle Scholar
  79. Stadler P, Becker A, Feldmann HJ et al (1999) Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 44:749–754PubMedCrossRefGoogle Scholar
  80. Staib P, Staltmeier E, Neurohr K (2005) Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci. Br J Haematol 128:783–791PubMedCrossRefGoogle Scholar
  81. Steel GG (1979) Terminology in the description of drug-radiation interactions. Int J Radiat Oncol Biol Phys 5:1145–1150PubMedGoogle Scholar
  82. Steel GG, Peckham MJ (1979) Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5:85–91PubMedGoogle Scholar
  83. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRefGoogle Scholar
  84. Sturm I, Petrowsky H, Volz R et al (2001) Analysis of p53/BAX/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: high BAX and p16(ink4a/CDKN2) identifies patients with good prognosis. J Clin Oncol 19:2272–2281PubMedGoogle Scholar
  85. Sui M, Dziadyk JM, Zhu X, Fan W (2004) Cell cycle-dependent antagonistic interactions between paclitaxel and gamma-radiation in combination therapy. Clin Cancer Res 10:4848–4857PubMedCrossRefGoogle Scholar
  86. Taghian AG, Abi-Raad R, Assaad SI et al (2005) Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J Clin Oncol 23:1951–1961PubMedCrossRefGoogle Scholar
  87. Tannock IF (1989) Combined modality treatment with radiotherapy and chemotherapy. Radiother Oncol 16:83–101PubMedCrossRefGoogle Scholar
  88. Tannock IF (1992) Potential for therapeutic gain from combined-modality treatment. Front Radiat Ther Oncol 26:1–15PubMedGoogle Scholar
  89. Tannock IF (1998) Conventional cancer therapy: promise broken or promise delayed? Lancet 351(Suppl 2):SII9–SII16PubMedCrossRefGoogle Scholar
  90. Teicher BA, Lazo JS, Sartorelli AC (1981) Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 41:73–81PubMedGoogle Scholar
  91. Thames HD, Suit HD (1986) Tumor radioresponsiveness versus fractionation sensitivity. Int J Radiat Oncol Biol Phys 12:687–691PubMedGoogle Scholar
  92. Trott KR (1990) Cell repopulation and overall treatment time. Int J Radiat Oncol Biol Phys 19:1071–1075PubMedGoogle Scholar
  93. Wahl AF, Donaldson KL, Fairchild C et al (1996) Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 2:72–79PubMedCrossRefGoogle Scholar
  94. Weber WA (2005) Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 46:983–995PubMedGoogle Scholar
  95. Wurschmidt F, Bardenheuer MJ, Muller WU, Molls M (2000) Chromosomal aberrations induced in mice bone marrow by treating with cisplatin and irradiation. Strahlenther Onkol 176:319–323PubMedCrossRefGoogle Scholar
  96. Yang LX, Douple EB, O’Hara JA, Wang HJ (1995) Production of DNA double-strand breaks by interactions between carboplatin and radiation: a potential mechanism for radiopotentiation. Radiat Res 143:309–315PubMedGoogle Scholar
  97. Yu YQ, Giocanti N, Averbeck D et al (2000) Radiation-induced arrest of cells in G2 phase elicits hypersensitivity to DNA double-strand break inducers and an altered pattern of DNA cleavage upon re-irradiation. Int J Radiat Biol 76:901–912PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  • Claus Belka
    • 1
  • Carsten Nieder
    • 2
  • Michael Molls
    • 2
  1. 1.Department of Radiation OncologyUniversity Hospital, Eberhard-Karls Universität TübingenTübingenGermany
  2. 2.Department of Radiation OncologyKlinikum rechts der Isar der Technischen Universität MünchenMunichGermany

Personalised recommendations